Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines Article

cited authors

  • Burgey, CS; Robinson, KA; Lyle, TA; Sanderson, PEJ; Lewis, SD; Lucas, BJ; Krueger, JA; Singh, R; Miller-Stein, C; White, RB; Wong, B; Lyle, EA; Williams, PD; Coburn, CA; Dorsey, BD; Barrow, JC; Stranieri, MT; Holahan, MA; Sitko, GR; Cook, JJ; McMasters, DR; McDonough, CM; Sanders, WM; Wallace, AA; Clayton, FC; Bohn, D; Leonard, YM; Detwiler, TJ; Lynch, JJ; Yan, YW; Chen, ZG; Kuo, L; Gardell, SJ; Shafer, JA; Vacca, JP

authors

Publication Date

  • February 13, 2003

webpage

published in

category

start page

  • 461

end page

  • 473

volume

  • 46

issue

  • 4